This article was originally published in The Gray Sheet
Expanded labeling approval for the Targis system includes a claim for treatment of the obstruction in the urethra caused by benign prostatic hyperplasia, the firm reports Aug. 7. No similar devices have been approved for this indication, the firm states. The system is currently approved for treatment BPH symptoms, such as frequent urination. Separately, the company reports revenues of $11.2 mil. for fiscal year 1998 ending June 30 compared to $5.5 mil. one year ago. Urologix books a larger net loss in FY 1998 ($15 mil.) versus its net loss in the year prior period ($8.2 mil.)
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.